North Carolina macular dystrophy: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
[[File:Autosomal_dominant_inheritance,_pedigree_example.png|Autosomal dominant inheritance, | {{SI}} | ||
{{Infobox medical condition | |||
| name = North Carolina macular dystrophy | |||
| image = [[File:Autosomal_dominant_inheritance,_pedigree_example.png|250px]] | |||
| caption = Autosomal dominant inheritance pattern | |||
| synonyms = MCDR1, NCMD | |||
| pronounce = | |||
| specialty = [[Ophthalmology]] | |||
| symptoms = [[Macular degeneration]], [[vision loss]] | |||
| onset = [[Childhood]] | |||
| duration = [[Lifelong]] | |||
| types = | |||
| causes = [[Genetic mutation]] | |||
| risks = | |||
| diagnosis = [[Ophthalmic examination]], [[genetic testing]] | |||
| differential = [[Age-related macular degeneration]], [[Stargardt disease]] | |||
| prevention = | |||
| treatment = [[Low vision aids]], [[supportive care]] | |||
| medication = | |||
| prognosis = [[Variable]], generally stable | |||
| frequency = Rare | |||
| deaths = | |||
}} | |||
'''North Carolina Macular Dystrophy''' ('''NCMD'''), also known as '''MCDR1''', is a rare [[genetic disorder]] characterized by the development of [[macular degeneration]] at birth or in early childhood, leading to varying degrees of [[visual impairment]]. This condition is notable for its autosomal dominant inheritance pattern, meaning a single copy of the altered gene in each cell is sufficient to cause the disorder. NCMD is specifically associated with mutations in the [[PRDM13]] gene located on chromosome 6, although the exact mechanism by which these mutations lead to the symptoms of the disease is not fully understood. | |||
==Symptoms and Diagnosis== | ==Symptoms and Diagnosis== | ||
The primary symptom of North Carolina Macular Dystrophy is [[visual impairment]], which ranges from mild to severe and is usually present from birth or develops in early childhood. The disease is characterized by the presence of drusen-like deposits and atrophic changes in the [[macula]], the part of the [[retina]] responsible for sharp, central vision. Unlike age-related [[macular degeneration]], NCMD symptoms typically do not progress significantly over time. | The primary symptom of North Carolina Macular Dystrophy is [[visual impairment]], which ranges from mild to severe and is usually present from birth or develops in early childhood. The disease is characterized by the presence of drusen-like deposits and atrophic changes in the [[macula]], the part of the [[retina]] responsible for sharp, central vision. Unlike age-related [[macular degeneration]], NCMD symptoms typically do not progress significantly over time. | ||
Diagnosis of NCMD is primarily based on clinical examination, including the use of [[ophthalmoscopy]] to observe the characteristic macular lesions. [[Genetic testing]] can confirm the diagnosis by identifying mutations in the PRDM13 gene. | Diagnosis of NCMD is primarily based on clinical examination, including the use of [[ophthalmoscopy]] to observe the characteristic macular lesions. [[Genetic testing]] can confirm the diagnosis by identifying mutations in the PRDM13 gene. | ||
==Treatment and Management== | ==Treatment and Management== | ||
There is currently no cure for North Carolina Macular Dystrophy. Treatment focuses on managing symptoms and supporting individuals with the condition to achieve their maximum potential vision. This may include the use of [[low vision aids]] and adaptive technologies to help affected individuals cope with their visual impairments. Regular monitoring by an [[ophthalmologist]] is recommended to address any changes in vision and associated conditions. | There is currently no cure for North Carolina Macular Dystrophy. Treatment focuses on managing symptoms and supporting individuals with the condition to achieve their maximum potential vision. This may include the use of [[low vision aids]] and adaptive technologies to help affected individuals cope with their visual impairments. Regular monitoring by an [[ophthalmologist]] is recommended to address any changes in vision and associated conditions. | ||
==Epidemiology== | ==Epidemiology== | ||
North Carolina Macular Dystrophy is a rare condition, with a higher prevalence reported in individuals of European descent. The disorder was first identified in a large family from North Carolina, which is how it received its name. However, cases have been reported worldwide, indicating that NCMD is not limited to any specific geographic region or ethnic group. | North Carolina Macular Dystrophy is a rare condition, with a higher prevalence reported in individuals of European descent. The disorder was first identified in a large family from North Carolina, which is how it received its name. However, cases have been reported worldwide, indicating that NCMD is not limited to any specific geographic region or ethnic group. | ||
==Genetics== | ==Genetics== | ||
The condition is caused by mutations in the PRDM13 gene, which plays a role in [[eye]] development. The inheritance pattern of NCMD is autosomal dominant, meaning that an individual only needs one copy of the mutated gene from one parent to be affected. There is a 50% chance of passing the condition on to offspring if one parent carries the mutation. | The condition is caused by mutations in the PRDM13 gene, which plays a role in [[eye]] development. The inheritance pattern of NCMD is autosomal dominant, meaning that an individual only needs one copy of the mutated gene from one parent to be affected. There is a 50% chance of passing the condition on to offspring if one parent carries the mutation. | ||
==Research== | ==Research== | ||
Research into North Carolina Macular Dystrophy is ongoing, with studies focusing on understanding the underlying genetic mechanisms and finding effective treatments. Advances in [[gene therapy]] and regenerative medicine offer hope for future interventions that could potentially restore vision or halt the progression of the disease. | Research into North Carolina Macular Dystrophy is ongoing, with studies focusing on understanding the underlying genetic mechanisms and finding effective treatments. Advances in [[gene therapy]] and regenerative medicine offer hope for future interventions that could potentially restore vision or halt the progression of the disease. | ||
[[Category:Eye diseases]] | [[Category:Eye diseases]] | ||
[[Category:Genetic disorders]] | [[Category:Genetic disorders]] | ||
[[Category:Rare diseases]] | [[Category:Rare diseases]] | ||
{{medicine-stub}} | {{medicine-stub}} | ||
Latest revision as of 04:52, 6 April 2025
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD medical weight loss NYC and sleep center NYC
| North Carolina macular dystrophy | |
|---|---|
| |
| Synonyms | MCDR1, NCMD |
| Pronounce | |
| Specialty | Ophthalmology |
| Symptoms | Macular degeneration, vision loss |
| Complications | N/A |
| Onset | Childhood |
| Duration | Lifelong |
| Types | |
| Causes | Genetic mutation |
| Risks | |
| Diagnosis | Ophthalmic examination, genetic testing |
| Differential diagnosis | Age-related macular degeneration, Stargardt disease |
| Prevention | |
| Treatment | Low vision aids, supportive care |
| Medication | |
| Prognosis | Variable, generally stable |
| Frequency | Rare |
| Deaths | |
North Carolina Macular Dystrophy (NCMD), also known as MCDR1, is a rare genetic disorder characterized by the development of macular degeneration at birth or in early childhood, leading to varying degrees of visual impairment. This condition is notable for its autosomal dominant inheritance pattern, meaning a single copy of the altered gene in each cell is sufficient to cause the disorder. NCMD is specifically associated with mutations in the PRDM13 gene located on chromosome 6, although the exact mechanism by which these mutations lead to the symptoms of the disease is not fully understood.
Symptoms and Diagnosis[edit]
The primary symptom of North Carolina Macular Dystrophy is visual impairment, which ranges from mild to severe and is usually present from birth or develops in early childhood. The disease is characterized by the presence of drusen-like deposits and atrophic changes in the macula, the part of the retina responsible for sharp, central vision. Unlike age-related macular degeneration, NCMD symptoms typically do not progress significantly over time. Diagnosis of NCMD is primarily based on clinical examination, including the use of ophthalmoscopy to observe the characteristic macular lesions. Genetic testing can confirm the diagnosis by identifying mutations in the PRDM13 gene.
Treatment and Management[edit]
There is currently no cure for North Carolina Macular Dystrophy. Treatment focuses on managing symptoms and supporting individuals with the condition to achieve their maximum potential vision. This may include the use of low vision aids and adaptive technologies to help affected individuals cope with their visual impairments. Regular monitoring by an ophthalmologist is recommended to address any changes in vision and associated conditions.
Epidemiology[edit]
North Carolina Macular Dystrophy is a rare condition, with a higher prevalence reported in individuals of European descent. The disorder was first identified in a large family from North Carolina, which is how it received its name. However, cases have been reported worldwide, indicating that NCMD is not limited to any specific geographic region or ethnic group.
Genetics[edit]
The condition is caused by mutations in the PRDM13 gene, which plays a role in eye development. The inheritance pattern of NCMD is autosomal dominant, meaning that an individual only needs one copy of the mutated gene from one parent to be affected. There is a 50% chance of passing the condition on to offspring if one parent carries the mutation.
Research[edit]
Research into North Carolina Macular Dystrophy is ongoing, with studies focusing on understanding the underlying genetic mechanisms and finding effective treatments. Advances in gene therapy and regenerative medicine offer hope for future interventions that could potentially restore vision or halt the progression of the disease.
